Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.63 |
| ▸ | PLG | P00747 | 6/20 | 0.61 |
| ▸ | F2 | P00734 | 5/20 | 0.58 |
| ▸ | F10 | P00742 | 5/20 | 0.58 |
| ▸ | F7 | P08709 | 3/20 | 0.58 |
| ▸ | PLAT | P00750 | 2/20 | 0.54 |
| ▸ | HPN | P05981 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519390 | 0.84 | PLAU (0.86) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL12348362 | 0.83 | PLAU (0.79) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL14519369 | 0.83 | PLAU (0.74) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL5517426 | 0.83 | PLAU (0.83) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL14355116 | 0.83 | PLAU (0.83) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL24312880 | 0.82 | PLAU (0.81) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL21409923 | 0.81 | MEN1 (0.68) | — | |
| SCHEMBL563497 | 0.80 | F2 (0.50) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL21856215 | 0.80 | PLAU (0.69) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL29367440 | 0.80 | PLAU (0.73) | PLAUPRSS1PLGF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829035-B2 | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| EP-2436683-B1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL CO (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | BDNF, NGF, NTRK2 | PLAU 1066/4885PRSS1 1070/4885PLG 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.